ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2055

TEAM-Managed Care of Biological Patients At A Canadian Centre

Melissa Deamude1, Dawn Heap2, Melanie Kanellos2, Debbie Kislinsky3, Kathy Kislinsky1, Cynthia Mech4, Helena Ross1, Peggy Saldanha3, Lauri Vanstone5, Kathleen Brown6 and William G. Bensen7, 1Dr. William G. Bensen, Rheumatology Health Team, St. Joseph's Hospital Hamilton, Hamilton, ON, Canada, 2Dr. Bensen's Rheumatology Clinic, Hamilton, ON, Canada, 3Dr. William Bensen Rheumatology Clinic, Hamilton, ON, Canada, 4Dr. William G. Bensen, Rheumatology Health Team, Dr. Bensen's Rheumatology Clinic, Hamilton, ON, Canada, 5Dr. William Bensen Rheumatology Biologic Clinic, Rheumatology Health Team, Hamilton, ON, Canada, 6Dr. William Bensen Rheumatology Clinic, Rheumatology Health Team, St. Joseph's Hospital Hamilton, Hamilton, ON, Canada, 7Department of Medicine, Division of Rheumatology, St. Joseph's Hospital and McMaster University, Hamilton, ON, Canada

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: biologic response modifiers, Health education, inflammatory arthritis, practice guidelines and quality of care

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Quality Measures and Innovations in Practice Management and Care Delivery

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Managing complex arthritic patients with biologics is exacting and time consuming.  As a result in January 2008 we established a separate biologic clinic with a clinic manager and team of experienced Registered Nurses linked to the general rheumatology clinic and early inflammatory arthritis clinic to assess, initiate, and follow patients with Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS), and Psoriatic Arthritis (PsA) needing to transition to biologic treatment and requiring care and follow-up while on biologics.  This team approach using experienced rheumatology nurses allows for triaging and timely access to care.

Methods:

Approximately 770 patients, 60% RA, 20% PsA and 20% AS are being followed in the biologic program.  All patients are initially assessed by an RN, examined to a standard protocol and then the treatment, assessment and plan of care is reviewed by the attending rheumatologist.  The clinic is structured using a primary care nursing model which promotes continuity and a patient centered therapeutic approach to care. Nurses are responsible for assessing their patients providing disease and treatment related heath teaching and providing injection training. The nurses also perform the clinical outcome measurements including spondylarthropathy measures, joint evaluations and administration and scoring of patient reported outcome questionnaires. The team manages and reviews routine labs and diagnostics daily, provides follow-up calls to patients to discuss adverse events, flares, concerns and treatment related inquiries.  Patients are seen a minimum of 3 times per year with most followed 6 times per year because of flares, co-morbidities, treatment adjustment or financial issues. The clinic operates as a primary point of contact for organizing management of co-morbidities, infusions and injections and ensures patients are being treated to target. The nurses are occasional speakers at national and regional rheumatology meetings to share best practices on the management of biological patients and how a team-based approach can improve efficiency and promote better patient outcomes. 

 Results:

This rheumatology health team managing patients on biologic treatment has exponentially grown and has worked well over a four-year period.  The team approach allows one rheumatologist to follow 5-7 times the number of patients seen by the average rheumatologist who does not have the team support.  Currently in Canada we have approximately 1/3 of the rheumatologists we need for optimal care and a team based approach can help fill this gap, reducing the burden on the health care system with fewer visits to urgent care or Emergency departments.  The team assesses 3-5 new patients a week for biologics and starts 2-3 patients per week on biologics. 

Conclusion:

The goal in the biologic clinic is treating to target for remission or lowest disease activity possible within the shortest period of time. This team approach to care has resulted in improved adherence to therapy, less risks and reported adverse events, improved safety monitoring and better patient satisfaction.


Disclosure:

M. Deamude,
None;

D. Heap,
None;

M. Kanellos,
None;

D. Kislinsky,
None;

K. Kislinsky,
None;

C. Mech,
None;

H. Ross,
None;

P. Saldanha,
None;

L. Vanstone,
None;

K. Brown,
None;

W. G. Bensen,

Abbott, Amgen, Astra Zeneca, BMS, Merck-Schering, Janssen, Lilly, Novartis, Pfizer and Wyeth, Proctor and Gamble, Roche, Sanofi Aventis, Servier, UCB, Warner Chilcott ,

.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/team-managed-care-of-biological-patients-at-a-canadian-centre/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology